SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India advances as USFDA completes inspection at its Gagillapur facility

17 Oct 2016 Evaluate

Granules India is currently trading at Rs. 121.95, up by 1.95 points or 1.63% from its previous closing of Rs. 120.00 on the BSE.

The scrip opened at Rs. 123.35 and has touched a high and low of Rs. 125.60 and Rs. 121.20 respectively. So far 3,64,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 164.45 on 01-Dec-2015 and a 52 week low of Rs. 101.25 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 125.60 and Rs. 117.75 respectively. The current market cap of the company is Rs. 2,648.29 crore.

The promoters holding in the company stood at 51.04%, while Institutions and Non-Institutions held 9.09% and 39.87% respectively.

Granules India’s Gagillapur facility located at Hyderabad in state of Telangana, has successfully completed US Food and Drug Administration (USFDA) inspection without any observations. This facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).

The company has recently received approval from USFDA for anti-inflammatory drug Ibuprofen tablets in the US market. The regulator has approved Abbreviated New Drug Application (ANDA) for Ibuprofen tablets USP, 200 mg (OTC) filed by the pharma major.

Granules India produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.


Granules India Share Price

654.40 3.60 (0.55%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×